UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.989

Sortiert nach

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2046-2054

2012

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management

The oncologist (Dayton, Ohio), 2007-05, Vol.12 (5), p.610-621

2007

Link zum Volltext

Verfügbarkeit prüfen

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Journal of clinical oncology, 2009-09, Vol.27 (26), p.4247-4253

2009

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2319-2326

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

JAMA : the journal of the American Medical Association, 2003-10, Vol.290 (16), p.2149

2003

Link zum Volltext

Verfügbarkeit prüfen

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Science translational medicine, 2011-03, Vol.3 (75), p.75ra26

2011

Link zum Volltext

Verfügbarkeit prüfen

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC

The oncologist (Dayton, Ohio), 2009-04, Vol.14 (4), p.399-411

2009

Link zum Volltext

Verfügbarkeit prüfen

Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2007-02, Vol.25 (5), p.587-595

2007

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

Journal of clinical oncology, 2010-02, Vol.28 (6), p.911-917

2010

Link zum Volltext

Verfügbarkeit prüfen

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-06, Vol.28 (18), p.3076-3083

2010

Link zum Volltext

Verfügbarkeit prüfen

Multipotent Myoepithelial Progenitor Cells Are Born Early during Airway Submucosal Gland Development

American journal of respiratory cell and molecular biology, 2017-06, Vol.56 (6), p.716-726

2017

Link zum Volltext

Verfügbarkeit prüfen

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Proceedings of the National Academy of Sciences - PNAS, 2015-02, Vol.112 (5), p.1547-1552

2015

Link zum Volltext

Verfügbarkeit prüfen

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Journal of clinical oncology, 2008-05, Vol.26 (15), p.2442-2448

2008

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-02, Vol.28 (6), p.918-927

2010

Link zum Volltext

Verfügbarkeit prüfen

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story

Annual review of medicine, 2008-01, Vol.59 (1), p.429-442

2008

Link zum Volltext

Verfügbarkeit prüfen

Depletion of Airway Submucosal Glands and TP63 + KRT5 + Basal Cells in Obliterative Bronchiolitis

American journal of respiratory and critical care medicine, 2018-04, Vol.197 (8), p.1045-1057

2018

Link zum Volltext

Verfügbarkeit prüfen

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients

Journal of thoracic oncology, 2009-03, Vol.4 (3), p.281-283

2009

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Clinical cancer research, 2009-04, Vol.15 (7), p.2552-2558

2009

Link zum Volltext

Verfügbarkeit prüfen

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

The New England journal of medicine, 2004-05, Vol.350 (21), p.2129-2139

2004

Link zum Volltext

Verfügbarkeit prüfen

Palliative Care Medical Education in European Universities: A Descriptive Study and Numerical Scoring System Proposal for Assessing Educational Development

Journal of pain and symptom management, 2015-10, Vol.50 (4), p.516-523.e2

2015

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2012-10, Vol.7 (10), p.1602-1608

2012

Link zum Volltext

Verfügbarkeit prüfen

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Clinical cancer research, 2006-07, Vol.12 (13), p.3908-3914

2006

Link zum Volltext

Verfügbarkeit prüfen

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study

Journal of thoracic oncology, 2014-09, Vol.9 (9), p.1332-1339

2014

Link zum Volltext

Verfügbarkeit prüfen

Irreversible Inhibitors of the EGF Receptor May Circumvent Acquired Resistance to Gefitinib

Proceedings of the National Academy of Sciences - PNAS, 2005-05, Vol.102 (21), p.7665-7670

2005

Link zum Volltext

Verfügbarkeit prüfen

Highly Efficient Transgenesis in Ferrets Using CRISPR/Cas9-Mediated Homology-Independent Insertion at the ROSA26 Locus

Scientific reports, 2019-02, Vol.9 (1), p.1971-1971, Article 1971

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.989

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.817)
Mit Volltextzugriff
(1.704)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC

Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

Multipotent Myoepithelial Progenitor Cells Are Born Early during Airway Submucosal Gland Development

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story

Depletion of Airway Submucosal Glands and TP63 + KRT5 + Basal Cells in Obliterative Bronchiolitis

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Palliative Care Medical Education in European Universities: A Descriptive Study and Numerical Scoring System Proposal for Assessing Educational Development

A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study

Irreversible Inhibitors of the EGF Receptor May Circumvent Acquired Resistance to Gefitinib

Highly Efficient Transgenesis in Ferrets Using CRISPR/Cas9-Mediated Homology-Independent Insertion at the ROSA26 Locus

Suchergebnisse filtern